Literature DB >> 22412050

Epidermal growth factor receptor mutations in malignant pleural and peritoneal mesothelioma.

Yasunori Enomoto1, Takahiko Kasai, Maiko Takeda, Masato Takano, Kohei Morita, Eiji Kadota, Norishige Iizuka, Hiroshi Maruyama, Joji Haratake, Yu Kojima, Naoya Ikeda, Naoki Inatsugi, Akitaka Nonomura.   

Abstract

BACKGROUND: Epidermal growth factor receptor (EGFR) gene mutation at the kinase domain and EGFR gene amplification are reported to be predictors of the response to EGFR tyrosine kinase inhibitors in lung cancer cases. In malignant mesothelioma (MM), the role of EGFR is less clear.
METHODS: Thirty-eight MM specimens were submitted to EGFR mutation evaluation, and compared with the results of immunohistochemical staining and fluorescence in situ hybridization (FISH) analysis. DNA was extracted from paraffin blocks and PCR was performed to amplify exon regions 18-21 of the EGFR gene. Direct sequencing of the purified PCR products was performed.
RESULTS: Five EGFR missense mutations were detected in six of the 38 patients (16%); two of these mutations were novel, two were originally detected in non-small cell lung carcinoma, and one resembled a location previously noted for malignant peritoneal mesothelioma.
CONCLUSION: As far as the authors are aware there has been no report of the EGFR mutation of MM in Japanese cases, but in this study EGFR missense mutations were detected in some cases. EGFR mutation results were not related to immunohistochemical and FISH analysis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22412050     DOI: 10.1136/jclinpath-2011-200631

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  8 in total

1.  EGFR-targeted pemetrexed therapy of malignant pleural mesothelioma.

Authors:  Liang Yang; Hanghang Fang; Jingjing Jiang; Yongjie Sha; Zhiyuan Zhong; Fenghua Meng
Journal:  Drug Deliv Transl Res       Date:  2021-11-20       Impact factor: 5.671

2.  Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma.

Authors:  Lindsay A Marek; Trista K Hinz; Anne von Mässenhausen; Kyle A Olszewski; Emily K Kleczko; Diana Boehm; Mary C Weiser-Evans; Raphael A Nemenoff; Hans Hoffmann; Arne Warth; Joseph M Gozgit; Sven Perner; Lynn E Heasley
Journal:  Mol Cancer Res       Date:  2014-06-25       Impact factor: 5.852

3.  BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma.

Authors:  Hakan Alakus; Shawn E Yost; Brian Woo; Randall French; Grace Y Lin; Kristen Jepsen; Kelly A Frazer; Andrew M Lowy; Olivier Harismendy
Journal:  J Transl Med       Date:  2015-04-16       Impact factor: 5.531

4.  Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma In Vitro and In Vivo.

Authors:  Zhi-Ran Yang; Zhi-Gao Chen; Xue-Mei Du; Yan Li
Journal:  Front Oncol       Date:  2020-12-07       Impact factor: 6.244

5.  Establishment and histopathological study of patient-derived xenograft models and primary cell lines of epithelioid malignant peritoneal mesothelioma.

Authors:  Zhi-Ran Yang; Zhi-Gao Chen; Zhong-He Ji; Yu-Lin Lin; Jue Zhang; Ru Ma; Zhao Li; Xi Jiang; Qian Chen; Xue-Mei Du; Yan Li
Journal:  Exp Anim       Date:  2021-01-21

6.  KRAS signaling in malignant pleural mesothelioma.

Authors:  Antonia Marazioti; Anthi C Krontira; Sabine J Behrend; Georgia A Giotopoulou; Giannoula Ntaliarda; Anne-Sophie Lamort; Georgios T Stathopoulos; Christophe Blanquart; Hasan Bayram; Marianthi Iliopoulou; Malamati Vreka; Lilith Trassl; Mario A A Pepe; Caroline M Hackl; Laura V Klotz; Stefanie A I Weiss; Ina Koch; Michael Lindner; Rudolph A Hatz; Juergen Behr; Darcy E Wagner; Helen Papadaki; Sophia G Antimisiaris; Didier Jean; Sophie Deshayes; Marc Grégoire; Özgecan Kayalar; Deniz Mortazavi; Şükrü Dilege; Serhan Tanju; Suat Erus; Ömer Yavuz; Pınar Bulutay; Pınar Fırat; Ioannis Psallidas; Magda Spella; Ioanna Giopanou; Ioannis Lilis
Journal:  EMBO Mol Med       Date:  2021-12-13       Impact factor: 12.137

7.  Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma.

Authors:  R Mezzapelle; U Miglio; O Rena; A Paganotti; S Allegrini; J Antona; F Molinari; M Frattini; G Monga; O Alabiso; R Boldorini
Journal:  Br J Cancer       Date:  2013-04-04       Impact factor: 7.640

Review 8.  Mesothelioma treatment: Are we on target? A review.

Authors:  Birgitta I Hiddinga; Christian Rolfo; Jan P van Meerbeeck
Journal:  J Adv Res       Date:  2014-12-01       Impact factor: 10.479

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.